Clinical Trial Update: Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update on Gardasil®9 in immunocompromised patients assessing safety, tolerability, and immunogenicity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• Human Papillomavirus Infection
• Transplant-related Immunosuppression

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Human Papilloma Virus, Hiv | Phase 3 | Status: COMPLETED | Results posted: 2020-12-11